Eli Lilly Announces Foundayo Met Primary Endpoint At Week 52 In ATTAIN-OSA Trial To Reduce Apnea-Hypopnea Index; Lowers Sleep Apnea-Specific Hypoxic Burden By Up To An Average Of 55.9%

Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight, with and without the use of positive airway pressure (PAP) therapy. At 52 weeks, Foundayo met the primary endpoint, significantly reducing the apnea-hypopnea index (AHI), the standard measure of sleep apnea severity, as well as improving weight and other cardiovascular risk factors.1 The results were presented today at the American Heart Association (AHA) Scientific Sessions 2026 and simultaneously published in JAMA.